Targeted Therapies - Changing Cancer Treatments to Benefit Patients
Sign up for free
Listen to this episode and many more. Enjoy the best podcasts on Spreaker!
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Recorded during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 2 - 6, 2017 in Chicago, Ill, Sonia Portillo and Peter Hofland, the team...
show moreAstellas currently has several highly targeted drugs in (early) development and clinical trials. One of these investigational agents is enfortumab vedotin, which is demonstrating promising results for metastatic urothelial cancer patients that fail checkpoint inhibitor therapies or CPIs.
Enfortumab vedotin is an antibody-drug conjugate or ADC designed to deliver the cell-killing, microtubule-disrupting, agent called monomethyl auristatin E or MMAE to the target Nectin-4, a cell adhesion molecule identified as an ADC target by Astellas, which is expressed on many solid tumors.
Antibody-drug conjugates or ADCs are a new class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound.
These novel, targeted agents combine the unique and very sensitive targeting capabilities of antibodies allowing sensitive discrimination between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.
Astellas' investigational ADC enfortumab vedotin uses Seattle Genetics’ proprietary linker technology.
Information
Author | Peter Hofland |
Organization | Peter Hofland |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company